Brighton Jones LLC’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Brighton Jones LLC’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,923	Closed	-$129K	–	676
2024 Q2	$129K	Hold	16,923	–	–	﹤0.01%	599
2024 Q1	$152K	Buy	+16,923	New	+$149K	0.01%	593
2023 Q4	–	Sell	-16,925	Closed	-$102K	–	615
2023 Q3	$102K	Hold	16,925	–	–	0.01%	523
2023 Q2	$117K	Buy	16,925 +153	+0.9%	+$1.01K	0.01%	525
2023 Q1	$263K	Buy	16,772 +78	+0.5%	+$1.53K	0.02%	410
2022 Q4	$334K	Sell	16,694 -9	-0.1%	-$179	0.02%	313
2022 Q3	$298K	Buy	16,703 +9	+0.1%	+$193	0.02%	334
2022 Q2	$371K	Hold	16,694	–	–	0.02%	302
2022 Q1	$464K	Hold	16,694	–	–	0.02%	290
2021 Q4	$758K	Hold	16,694	–	–	0.04%	211
2021 Q3	$1.39M	Buy	16,694 +50	+0.3%	+$4.14K	0.07%	125
2021 Q2	$1.58M	Hold	16,644	–	–	0.08%	111
2021 Q1	$2.77M	Buy	+16,644	New	+$2.2M	0.16%	62

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PPW

Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Brighton Jones LLC's ONCT Position: Q3 2024 in Review

Brighton Jones LLC sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2024, closing a stake of 16,923 shares — an estimated $129K sold.

Brighton Jones LLC first reported a position in ONCT in Q1 2021 and held it in 13 quarters. The position peaked at $2.77M in Q1 2021. 23 funds tracked by Wall St. Rank hold ONCT as of Q3 2024.

Brighton Jones LLC reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Brighton Jones LLC sold 16,923 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $129K.
Brighton Jones LLC first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
Brighton Jones LLC's Oncternal Therapeutics, Inc. Common Stock position peaked at $2.77M in Q1 2021.
23 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Brighton Jones LLC's 13F filing for Q3 2024, filed 22 Oct 2024.